NGS Disease Research Panels

ClearSeq Constitutional Disease

Cardiomyopathy[HS] and Arrhythmia[HS] research panels

Powered by HaloPlex[HS] technology

Benefits

Confidence in Genomic Content

- Comprehensive content tailored to cardiomyopathy and arrhythmia
- Developed in conjunction with top clinical research leaders

Ease of Use From Sample to Analysis

- Simple, fast, and automatable workflow
- SureCall software for intuitive variant analysis and report formats

Results You Can Trust

- Amplicon redundancy providing better target coverage and less PCR artifacts
- Premium performance with excellent enrichment efficiency and sequencing uniformity
- Molecular barcoding enabling variant calls at unparalleled sensitivity and accuracy

Next generation sequencing has revolutionized the field of genetics by enabling laboratories to uncover sequence level variations quickly and cost effectively. In order to harness the power of next generation sequencing for genetic anomalies known to be associated with specific disease states, it is critical to target these specific genomic regions.

ClearSeq Cardiomyopathy

The ClearSeq Cardiomyopathy (catalog) is a next generation sequencing target enrichment panel designed specifically for inherited forms of cardiomyopathy. Following a careful review of cardiomyopathy publications as well as information available from GeneReviews, an NIH online resource, 34 genes known to be associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy have been included. As shown in the table below, there is substantial overlap in some genes associated with different cardiomyopathy types, and the ability to sequence all of the genes simultaneously enables laboratories to create a comprehensive cardiomyopathy profile for clinical research samples in one efficient, cost effective application.



www.agilent.com/genomics/ngs

Agilent

Trusted Answers

ClearSeq Arrhythmia

Targeting genomic regions known to be associated with four inherited arrhythmia related heart disorders, ClearSeq Arrhythmia (made-to-order) is a next generation sequencing target enrichment panel. It is a result of a thorough review of publications for arrhythmia and drew on information in GeneReviews in order to incorporate 21 genes known to correlate with Long QT syndrome, Short QT syndrome, Brugada syndrome, and Catecholaminergic polymorphic ventricular tachycardia. The genes associated with different types of arrhythmia are overlapping in some cases, as shown in the table below, and using ClearSeq Arrhythmia, a comprehensive arrhythmia profile can be assembled for clinical research samples.



From Sample to Result in Less than 2 Days

1 Order ClearSeq panel

Cardiomyopathy
G9943A - ClearSeq Cardiomyopathy, HS, ILM, 16 rxn
G9943B - ClearSeq Cardiomyopathy, HS, ILM, 96 rxn

or

Arrhythmia
Made-to-Order
G9954C #005 - ClearSeq Arrhythmia, HS, ILM, 48 rxn
G9954B #005 - ClearSeq Arrhythmia, HS, ILM, 96 rxn

Visit SureDesign
www.agilent.com/genomics/suredesign

2 Prepare samples and sequence

3 Analyze data, print/export results
SureCall

Premium Target Enrichment Performance



Figure 1. Results from Illumina MiSeq runs; Uniformity calculated as percent bases covered at ≥ 10% of mean coverage.

Request more information or buy online:
www.agilent.com/genomics/ngs

For Research Use Only. Not for use in diagnostic procedures.

This information is subject to change without notice.

PR7000-0350

Published in the USA, September 27, 2017
5991-2525EN

Agilent
Trusted Answers